Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections.

Abstract

PURPOSE:

To compare the 12-month efficacy of 1 initial intravitreal injection of an anti-vascular endothelial growth factor (VEGF) agent followed by pro re nata (PRN) dosing with that of 3 initial monthly injections followed by PRN dosing in patients with macular edema (ME) after central retinal vein occlusion (CRVO).

METHODS:

Twenty-nine eyes received 1 initial injection (1+PRN group) and 20 received 3 monthly injections (3+PRN group).

RESULTS:

At month 12, changes in logMAR visual acuity from baseline were -0.172 ± 0.372 and -0.142 ± 0.317 in the 1+PRN and 3+PRN groups, respectively; the difference was not significant (p = 0.769). The number of anti-VEGF injections administered in the 3+PRN group (5.9 ± 2.1) was significantly greater than that in the 1+PRN group (4.1 ± 2.8; p = 0.022).

CONCLUSION:

When used for ME after CRVO, a 1+PRN regimen achieved 12-month outcomes similar to those of a 3+PRN regimen with fewer injections.

• Authors: Rie Osaka, Yuki Muraoka, Yuko Miwa, Koichiro Manabe, Mamoru Kobayashi, Yukari Takasago, Sotaro Ooto, Tomoaki Murakami, Kiyoshi Suzuma, Yuto Iida, Akitaka Tsujikawa
• Journal: Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (Ophthalmologica) Vol. 239 Issue 1 Pg. 27-35 ( 2018) ISSN: 1423-0267 [Electronic] Switzerland
• PMID: 28946138 (Publication Type: Comparative Study, Journal Article)
• Copyright: © 2017 S. Karger AG, Basel.

Chemical References

• Angiogenesis Inhibitors
• Vascular Endothelial Growth Factor A
• Ranibizumab

Topics

• Adult
• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors (administration & dosage)
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Female
• Fluorescein Angiography
• Follow-Up Studies
• Fundus Oculi
• Humans
• Intravitreal Injections
• Macula Lutea (pathology)
• Macular Edema (diagnosis, drug therapy, etiology)
• Male
• Middle Aged
• Prospective Studies
• Ranibizumab (administration & dosage)
• Retinal Vein Occlusion (complications, diagnosis, drug therapy)
• Time Factors
• Tomography, Optical Coherence
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity